GlassScriptPhysician profile
Rochelle J Brotsky
NPI 1649226739
$1,110.58
in general payments reported to CMS, 2019-2025
16 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $35.70 · 2021: $17.40 · 2022: $191 · 2023: $69.19 · 2024: $137 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.53 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $288.30 | 2019-2025 | Cequa |
| Allergan, INC. | $255.61 | 2019 | |
| Amgen INC. | $126.35 | 2024-2025 | Tepezza |
| Iridex Corporation | $87.70 | 2022 | |
| Alcon Vision LLC | $83.41 | 2022-2025 | Tryptyr, Rocklatan |
| Dompe US, INC. | $43.78 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $39.48 | 2020-2022 | |
| Abbvie INC. | $37.57 | 2023-2024 | Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $28.08 | 2022-2024 | Miebo, Vyzulta |
| Genentech USA, INC. | $25.00 | 2023 | |
| Kala Pharmaceuticals, INC. | $22.19 | 2019 | |
| Harrow Eye, LLC | $18.45 | 2025 | Vevye |
| Notal Vision, INC. | $17.85 | 2022 | |
| Oyster Point Pharma, INC. | $13.70 | 2024 | Ryzumvi, Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochelle Brotsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.